February 1, 2008Seminars in Respiratory and Critical Care Medicine
Venous Thromboembolism Prophylaxis for the Medical Patient: Where Do We Stand?
Why the study?
Does low molecular weight heparin or fondaparinux prevent venous thromboembolism safely in acutely ill medical patients compared to unfractionated heparin or other methods?
Population
Acutely ill medical patients at moderate to high risk of venous thromboembolism
Comparison
Low molecular weight heparin or fondaparinux vs Unfractionated heparin, aspirin, warfarin, or…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform VTE prophylaxis favoring LMWH/fondaparinux in medical patients; leaves open need for updated RCTs.
Structured PICO
Does low molecular weight heparin or fondaparinux prevent venous thromboembolism safely in acutely ill medical patients compared to unfractionated heparin or other methods?
P
Population
Acutely ill medical patients at moderate to high risk of venous thromboembolism
I
Intervention
Low molecular weight heparin or fondaparinux
C
Comparator
Unfractionated heparin, aspirin, warfarin, or mechanical methods
O
Outcome
Prevention of venous thromboembolism (deep vein thrombosis or pulmonary embolism)hard clinical
Low molecular weight heparin and fondaparinux are the recommended agents for VTE prophylaxis in acutely ill medical patients due to efficacy and lower bleeding risk compared to unfractionated heparin.
Cite This Study
Yavin et al. (2008) studied this question.